Cost-Effectiveness and Clinical Utility of Pancreatic Cancer Non-Invasive Test in New-Onset Diabetes

These findings underscore the transformative clinical and economic value of early PC detection in high-risk patients with NOD. Implementing cfDNA testing during the first three years following diabetes onset has the potential to shift the diagnosis paradigm, leading to early interventions and meaningful improvements in expected survival, while remaining cost-effective.